TeleTrader - A step ahead of the market

The number of shares and votes in Active Biotech has changed as a result of the
exercise of employee stock options.

Today, the last trading day of the month, there are in total 65,961,573 shares
and votes in Active Biotech.


Lund, July 30, 2010
Active Biotech AB (publ)


For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail:hans.kolam@activebiotech.com


About Active Biotech
Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with
focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase
are laquinimod, an orally administered small molecule with unique
immunomodulatory properties for the treatment of multiple sclerosis, as well as
ANYARA for use in cancer targeted therapy, primarily of renal cancer. Further
key projects in clinical development comprise the three orally administered
compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex(TM) for RA. Please
visitwww.activebiotech.com for more information.


Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under the Financial Instruments Trading Act to make
the information in this press release public. The information was submitted for
publication at 08:30 a.m. CET on July 30, 2010.


[HUG#1429853]





Number of shares and votes in Active Biotech: http://hugin.info/1002/R/1429853/376845.pdf



This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE